Dry Eye Disease
Last updated: April 14th, 2022
Summary of Evidence
Loteprednol Etabonate (EYSUVIS)
Both loteprednol and artificial tears showed significantly improved Ocular surface disease index scores at 2, 4, and 8 weeks, with significantly more improvement in loteprednol group. Pretreatment with the latter also significantly reduced topical cyclosporine stinging.(Sheppard et.al., 2014) {Sheppard JD, Donnenfeld ED, Holland EJ, Slonim CB, Solomon R, Solomon KD, McDonald MB, Perry HD, Lane SS, Pflugfelder SC, Samudre SS. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Eye Contact Lens. 2014 Sep;40(5):289-96.}
Cyclosporine 0.09% (CEQUA)
CEQUA-treated patients demonstrated significant improvements in corneal and conjunctival staining.(Goldberg et.al., 2019) {Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease. Ophthalmology. 2019 Sep;126(9):1230-1237.}
Lifitegrast 5% (XIIDRA)
Lifitegrast significantly improved symptoms of eye dryness on eye dryness score, but did not improve ocular discomfort score compared to placebo.(Holland et.al. in OPUS, 2017) {Holland EJ, Luchs J, Karpecki PM, Nichols KK, Jackson MA, Sall K, Tauber J, Roy M, Raychaudhuri A, Shojaei A. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). Ophthalmology. 2017 Jan;124(1):53-60.}
Cyclosporine 0.05% (RESTASIS)
Cyclosporin A 0.05% and 0.1%, gave significantly greater improvements then vehicle in corneal staining and categorized Schirmer values, and in the subjective measures of blurred vision, need for concomitant artificial tears, and the physician’s evaluation of global response to treatment.(Sall et.al., 2000) {Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000 Apr;107(4):631-9.}
Autologous serum eyedrops
Refer below
Treatment of Meibomian gland dysfunction
Refer below